Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

Overview of attention for article published in Therapeutics and Clinical Risk Management, September 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#21 of 1,323)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 11 news outlets

twitter: 1 X user

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 37 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 8 publications that cite this research output.

8

The most recent citing publications are shown below. View all 8 publications that cite this research output on Dimensions.

Momelotinib: First Approval

Article in Drugs (November 2023)

Anemia in myelofibrosis: Current and emerging treatment options

Article in Critical Reviews in Oncology/Hematology (November 2022)

Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors

Article in Current Opinion in Oncology (August 2022)